Recalling the desperate fight for life that was waged by juvenile diabetes patients not even a century ago, "Breakthrough: The Dramatic Story of the Discovery of Insulin" will be on view at the New York Historical Society from October 2010 through January 2011.
Each year, community pharmacists are recognized by their peers through nominations for Drug Topics' annual Top Independent Pharmacists awards, which honor 3 pharmacists or pharmacy teams for their contributions to local life.
From medication therapy management to diabetes self-management education programs, retail pharmacists have begun to solidify a new role for themselves on the healthcare team.
Pfizer plans to acquire King Pharmaceuticals for $3.6 billion in cash, expanding its current portfolio of treatments for pain relief and pain management.
Abbott is complying with FDA's request to withdraw sibutramine (Meridia) from the U.S. market because the obesity drug may pose unnecessary cardiovascular (CV) risks to patients.
The DEA has changed its policy and now recognizes long-term-care nurses as agents of prescribers of Schedule C-III through C-V medications, according to a Federal Register notice released today.
Underlying a recent FDA-hosted public meeting and workshop was the question of how FDA as a regulatory agency should increase its current oversight of clinical laboratories, specifically those developing genetic tests that may be offered at their own facilities or made available through direct-to-consumer channels.
Thirty-nine states now have a tool to help pharmacists identify at least some questionable prescriptions and suggest when a patient may be doctor-shopping or pharmacy-shopping in order to obtain controlled substances. That tool is the state prescription monitoring program.
Community pharmacists face a "War on Drugs" different from the one heard about on the news. This war doesn't even seem to be on lawmakers' radar.
Denying yourself food to protest the policies of a corporate behemoth seems a bit ... extreme. Nonetheless, such an action may be a legitimate warning about the state of retail pharmacy today.
A Congressional bill aims to boost the capacity for information exchange among state programs that monitor prescription controlled substances and seeks to provide continued grant funding to support such efforts.
Patients often bring their own set of challenges with them to the pharmacy counter and community pharmacists have taken notice. Many have responded by creating programs that not only help patients secure the medication they need, but also offer them ways to make the most of their treatment plans.
Pharmacists speak out about immunizations, sexism in the pharmacy, and $4 prescriptions.
Collaborative practice agreements between physicians and pharmacists will be a reality in Pennsylvania within the next couple of years.
A survey of new Rx, new generic, and new OTC products
San Francisco had the right idea when it banned the sale of tobacco in pharmacies. Then it turned around and allowed the sale in grocery stores and big-box stores. Wal-Mart and Safeway have pharmacies, and they keep on selling cigarettes. Forcing drugstores to take the high road is a lost cause.
The Washington State Board of Pharmacy is revisiting its rules requiring pharmacists to dispense emergency contraceptives.
In a novel collaboration with PBM giant CVS Caremark and its specialty pharmacy Generation Health, PGXL Laboratories will use its expertise in anticoagulants to improve the quality of patient care through pharmacogenetic testing, physician education, and drug-specific software programs.
While genetic testing can identify patients who will be nonresponsive to certain drug therapies, it can also suggest other drugs as treatment options that might work. These may include pharmaceuticals not usually considered for treatment of a particular cancer.
Generic manufacturers and consumer budgets are the big winners in the ongoing voluntary recall of millions of packages of pediatric liquid medications manufactured by McNeil Consumer Healthcare.
With so many best-selling name-brand drugs coming off patent over the next few years, the market for generics should expand markedly. In Drug Topics' special generics supplement, pharmacists from around the country offer their views.
The generic market is likely to remain very strong between now and 2015, but the combination of healthcare reform and a lack of significant drugs coming off patent means that the outlook between 2015 and 2020 is murkier.
There are some big names among the brand drugs that have recently come off patent and joined the burgeoning generics market.
In a recent survey by Medco Health Solutions Inc., only 66% of 1,092 patients with insurance surveyed "agreed that a generic drug is the same as the brand-name medication - many patients are still not comfortable using a generic and others still consider brand-name drugs to be superior."
The latest pharmacy technologies include IVR, telepharmacy, cell-phone-based automatic refill reminders, a compact robotic dispenser, remote dispensing, and CPOE pharmacy management.
